

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	3	5.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	6.5	107.5	(43.1-221.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	28	22.1	126.6	(84.1-183.0)
Female	0	0.1	nc	(nc-nc)	Female	10	19.0	52.5	(25.1-96.6)
<u>Lung and Bronchus</u>									
Male	6	3.0	200.3	(73.1-435.9)					
Female	2	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.3	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	26	21.1	123.0	(80.4-180.3)	Female	3	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	7	8.2	85.0	(34.0-175.1)	<u>Ovary</u>				
Female	11	6.7	165.0	(82.3-295.3)	Female	3	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	21.4	79.3	(46.2-127.0)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.1	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	60	76.4	78.6	(59.9-101.1)
Female	0	0.4	nc	(nc-nc)	Female	84	68.1	123.4	(98.5-152.8)
<u>Lung and Bronchus</u>									
Male	8	10.0	79.6	(34.3-156.9)					
Female	17	8.5	201.0	(117.0-321.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	42.6	108.0	(79.1-144.1)	Male	25	25.6	97.8	(63.3-144.4)
Female	18	17.5	103.0	(61.0-162.8)	Female	28	23.4	119.8	(79.6-173.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.1	nc	(nc-nc)	Male	6	6.6	90.3	(33.0-196.5)
Female	2	7.3	nc	(nc-nc)	Female	5	5.3	93.5	(30.1-218.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	28	22.6	123.9	(82.3-179.0)
Female	160	168.0	95.3	(81.1-111.2)	Female	26	22.7	114.3	(74.6-167.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	10	7.5	133.5	(63.9-245.6)	Male	14	15.7	89.3	(48.8-149.8)
<u>Colon / Rectum</u>					Female	10	8.3	120.3	(57.6-221.2)
Male	72	62.6	115.0	(90.0-144.8)	<u>Ovary</u>				
Female	73	67.1	108.8	(85.3-136.8)	Female	17	18.3	93.1	(54.2-149.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	10.8	92.7	(44.4-170.5)	Male	13	12.5	104.1	(55.4-178.1)
Female	6	3.4	175.4	(64.1-381.8)	Female	19	14.6	130.1	(78.3-203.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.8	nc	(nc-nc)	Male	151	161.0	93.8	(79.4-110.0)
Female	3	3.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	18	10.5	172.0	(101.9-271.9)
Male	19	19.0	100.0	(60.2-156.2)	Female	12	7.1	168.3	(86.9-294.0)
Female	6	13.1	45.6	(16.7-99.3)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.7	74.7	(24.1-174.3)
Male	11	6.7	164.6	(82.0-294.5)	<u>Thyroid</u>				
Female	2	2.0	nc	(nc-nc)	Male	8	6.0	132.8	(57.2-261.7)
<u>Leukemia</u>					Female	19	20.6	92.1	(55.4-143.8)
Male	26	14.0	186.3	(121.7-273.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	12.1	173.3	(107.2-264.9)	Female	29	35.7	81.2	(54.4-116.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	9.1	54.9	(17.7-128.1)	Male	616	566.6	108.7	(100.3-117.6)
Female	3	3.6	nc	(nc-nc)	Female	645	590.0	109.3	(101.0-118.1)
<u>Lung and Bronchus</u>									
Male	100	79.9	125.1	(101.8-152.2)					
Female	107	82.6	129.5	(106.1-156.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	8.4	154.4	(82.1-264.1)	Male	0	5.4	nc	(nc-nc)
Female	7	3.0	236.9	(94.9-488.1)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	24	32.0	74.9	(48.0-111.4)	Female	5	3.9	126.9	(40.9-296.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.5	nc	(nc-nc)
Male	13	12.8	101.7	(54.1-174.0)	<u>Ovary</u>				
Female	12	11.1	108.5	(56.0-189.5)	Female	2	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	2.3	261.7	(95.6-569.7)	Male	3	2.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	33	34.9	94.6	(65.1-132.8)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	6	4.1	145.8	(53.3-317.5)	Female	3	1.1	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.3	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.9	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	6	7.0	85.4	(31.2-185.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.0	nc	(nc-nc)	Male	126	118.3	106.5	(88.7-126.8)
Female	0	0.6	nc	(nc-nc)	Female	115	106.4	108.1	(89.3-129.8)
<u>Lung and Bronchus</u>									
Male	22	16.3	135.3	(84.7-204.8)					
Female	25	14.7	170.5	(110.3-251.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.8	104.0	(38.0-226.3)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	17	19.4	87.4	(50.9-140.0)
Female	0	0.1	nc	(nc-nc)	Female	5	11.6	43.1	(13.9-100.7)
<u>Lung and Bronchus</u>									
Male	5	2.9	174.0	(56.1-406.2)					
Female	1	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	23.3	150.3	(104.7-209.1)	Male	26	13.8	188.5	(123.1-276.2)
Female	11	8.4	131.1	(65.3-234.5)	Female	18	11.3	159.7	(94.6-252.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.5	179.8	(77.4-354.2)	Male	7	3.6	193.1	(77.4-397.8)
Female	5	3.6	140.2	(45.2-327.3)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	16	12.3	130.5	(74.5-211.9)
Female	114	84.4	135.0	(111.4-162.2)	Female	10	10.9	91.6	(43.9-168.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	3.7	nc	(nc-nc)	Male	6	8.7	68.9	(25.2-149.9)
<u>Colon / Rectum</u>					Female	3	4.1	nc	(nc-nc)
Male	32	34.3	93.4	(63.9-131.8)	<u>Ovary</u>				
Female	26	32.1	81.1	(53.0-118.9)	Female	11	9.0	122.0	(60.8-218.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.9	101.0	(36.9-219.8)	Male	10	6.9	145.9	(69.9-268.3)
Female	1	1.6	nc	(nc-nc)	Female	8	7.0	114.5	(49.3-225.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	107	87.6	122.2	(100.1-147.6)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	5.7	nc	(nc-nc)
Male	12	10.4	115.1	(59.4-201.0)	Female	2	3.4	nc	(nc-nc)
Female	3	6.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.9	170.7	(55.0-398.3)
Male	5	3.7	136.2	(43.9-317.9)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	9.9	50.3	(16.2-117.4)
Male	10	7.6	132.0	(63.2-242.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	5.8	239.7	(130.9-402.2)	Female	16	17.8	89.7	(51.2-145.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.0	nc	(nc-nc)	Male	352	308.0	114.3	(102.6-126.9)
Female	0	1.7	nc	(nc-nc)	Female	309	288.5	107.1	(95.5-119.7)
<u>Lung and Bronchus</u>									
Male	39	43.7	89.2	(63.4-121.9)					
Female	27	40.1	67.3	(44.3-97.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	45	36.1	124.6	(90.8-166.7)	Male	16	20.5	78.2	(44.6-126.9)
Female	18	13.4	134.6	(79.7-212.8)	Female	12	16.4	73.0	(37.7-127.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.2	80.4	(25.9-187.6)	Male	4	5.6	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	24	18.2	131.6	(84.3-195.8)
Female	120	126.6	94.8	(78.6-113.3)	Female	26	17.0	153.0	(99.9-224.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	5.1	nc	(nc-nc)	Male	15	13.0	115.8	(64.7-191.0)
<u>Colon / Rectum</u>					Female	9	6.2	144.5	(65.9-274.3)
Male	51	52.6	96.9	(72.2-127.4)	<u>Ovary</u>				
Female	61	50.5	120.8	(92.4-155.2)	Female	7	13.7	51.2	(20.5-105.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	9.1	76.7	(30.7-158.0)	Male	12	10.6	113.4	(58.5-198.1)
Female	3	2.6	nc	(nc-nc)	Female	6	11.1	54.1	(19.7-117.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.5	nc	(nc-nc)	Male	129	138.4	93.2	(77.8-110.7)
Female	0	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	9	8.8	102.8	(46.9-195.1)
Male	18	15.7	114.6	(67.9-181.1)	Female	5	5.3	94.6	(30.5-220.8)
Female	9	10.0	90.1	(41.1-171.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.9	nc	(nc-nc)
Male	8	5.7	140.9	(60.7-277.6)	<u>Thyroid</u>				
Female	1	1.6	nc	(nc-nc)	Male	7	4.4	157.6	(63.1-324.8)
<u>Leukemia</u>					Female	16	13.7	117.2	(66.9-190.3)
Male	10	11.1	89.7	(42.9-164.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	8.7	137.3	(70.9-239.9)	Female	37	27.6	134.0	(94.3-184.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	7.5	172.6	(91.8-295.1)	Male	498	473.2	105.2	(96.2-114.9)
Female	1	2.7	nc	(nc-nc)	Female	464	442.0	105.0	(95.6-115.0)
<u>Lung and Bronchus</u>									
Male	76	68.1	111.6	(87.9-139.7)					
Female	76	64.3	118.3	(93.2-148.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	11.1	99.5	(49.6-178.1)
Female	0	0.0	nc	(nc-nc)	Female	10	8.5	118.0	(56.5-217.0)
<u>Lung and Bronchus</u>									
Male	4	1.5	nc	(nc-nc)					
Female	2	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	22.4	76.1	(44.3-121.8)	Male	23	13.2	173.9	(110.2-260.9)
Female	5	8.2	60.8	(19.6-141.8)	Female	16	10.7	150.1	(85.7-243.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.1	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	9	11.7	77.2	(35.2-146.6)
Female	82	82.3	99.6	(79.2-123.7)	Female	9	10.6	85.3	(38.9-161.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	14	8.6	162.0	(88.5-271.9)
<u>Colon / Rectum</u>					Female	1	4.0	nc	(nc-nc)
Male	31	33.1	93.6	(63.6-132.8)	<u>Ovary</u>				
Female	30	31.0	96.9	(65.4-138.4)	Female	6	8.8	68.4	(25.0-148.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.9	102.3	(37.3-222.6)	Male	5	6.7	75.2	(24.2-175.4)
Female	3	1.6	nc	(nc-nc)	Female	7	6.8	103.2	(41.4-212.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	100	90.6	110.4	(89.8-134.3)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	8	5.4	147.2	(63.4-290.2)
Male	9	10.3	87.0	(39.7-165.2)	Female	3	3.2	nc	(nc-nc)
Female	2	6.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.2	87.0	(37.5-171.5)
Male	2	7.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	5.5	162.5	(74.1-308.5)	Female	16	17.9	89.4	(51.1-145.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.0	100.7	(32.5-235.1)	Male	322	303.4	106.1	(94.9-118.4)
Female	2	1.7	nc	(nc-nc)	Female	261	280.3	93.1	(82.2-105.1)
<u>Lung and Bronchus</u>									
Male	49	43.1	113.6	(84.0-150.2)					
Female	30	39.8	75.4	(50.8-107.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	15.7	159.0	(102.8-234.7)	Male	11	9.6	115.0	(57.3-205.9)
Female	6	5.2	115.1	(42.0-250.5)	Female	5	7.4	67.6	(21.8-157.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.4	106.9	(48.8-203.0)
Female	72	55.4	130.0	(101.7-163.7)	Female	5	6.9	72.5	(23.4-169.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	7	6.2	112.1	(44.9-231.0)
<u>Colon / Rectum</u>					Female	5	2.6	191.8	(61.8-447.6)
Male	20	23.5	85.2	(52.0-131.6)	<u>Ovary</u>				
Female	12	19.7	61.0	(31.5-106.6)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.2	120.4	(38.8-281.0)	Male	5	4.7	106.4	(34.3-248.4)
Female	1	1.0	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	56	62.8	89.2	(67.4-115.9)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	9	3.9	233.6	(106.6-443.5)
Male	9	7.3	122.7	(56.0-232.9)	Female	2	2.0	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.7	103.9	(41.6-214.2)
Male	6	5.1	117.6	(42.9-256.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.6	nc	(nc-nc)	Female	12	11.8	101.6	(52.4-177.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.5	nc	(nc-nc)	Male	217	214.3	101.3	(88.2-115.7)
Female	2	1.1	nc	(nc-nc)	Female	193	185.0	104.3	(90.1-120.1)
<u>Lung and Bronchus</u>									
Male	34	30.1	112.9	(78.2-157.8)					
Female	31	25.6	121.2	(82.3-172.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	17.1	105.0	(62.2-166.0)	Male	12	11.1	108.4	(55.9-189.3)
Female	3	5.9	nc	(nc-nc)	Female	18	9.0	199.9	(118.4-316.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	17	9.7	176.0	(102.5-281.8)
Female	80	68.2	117.2	(93.0-145.9)	Female	4	8.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	5	7.4	67.2	(21.6-156.7)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	17	26.2	64.8	(37.8-103.8)	<u>Ovary</u>				
Female	24	22.7	105.6	(67.7-157.2)	Female	6	7.1	84.2	(30.8-183.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.7	nc	(nc-nc)	Male	6	5.2	114.9	(42.0-250.1)
Female	2	1.2	nc	(nc-nc)	Female	12	4.9	244.5	(126.2-427.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	66	70.0	94.2	(72.9-119.9)
Female	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	4.3	nc	(nc-nc)
Male	2	8.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Female	7	4.9	143.2	(57.4-295.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.3	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	7	2.7	258.2	(103.5-532.1)
<u>Leukemia</u>					Female	15	8.4	178.6	(99.9-294.5)
Male	7	5.9	119.2	(47.8-245.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.4	nc	(nc-nc)	Female	16	14.3	111.7	(63.8-181.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.2	nc	(nc-nc)	Male	226	240.8	93.9	(82.0-106.9)
Female	1	1.2	nc	(nc-nc)	Female	252	220.6	114.3	(100.6-129.3)
<u>Lung and Bronchus</u>									
Male	25	33.0	75.8	(49.1-111.9)					
Female	29	29.1	99.6	(66.7-143.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.5	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	18	15.0	119.8	(71.0-189.4)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	3	6.6	nc	(nc-nc)	<u>Ovary</u>				
Female	5	5.5	90.6	(29.2-211.3)	Female	3	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	13	17.7	73.5	(39.1-125.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.7	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.0	nc	(nc-nc)	Male	46	59.7	77.0	(56.4-102.7)
Female	0	0.3	nc	(nc-nc)	Female	45	51.0	88.2	(64.3-118.0)
<u>Lung and Bronchus</u>									
Male	9	8.5	105.6	(48.2-200.4)					
Female	5	7.4	67.7	(21.8-158.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.9	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	8	10.8	74.1	(31.9-146.0)	Female	0	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Ovary</u>				
Female	8	4.9	162.9	(70.1-320.9)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	11.2	116.5	(62.0-199.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	36	38.2	94.2	(66.0-130.5)
Female	0	0.3	nc	(nc-nc)	Female	41	39.1	104.9	(75.3-142.3)
<u>Lung and Bronchus</u>									
Male	3	5.5	nc	(nc-nc)					
Female	5	5.6	89.4	(28.8-208.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.6	129.5	(47.3-281.8)	Male	4	2.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	26	17.2	151.5	(98.9-222.0)	Female	3	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	8	7.1	113.0	(48.6-222.6)	<u>Ovary</u>				
Female	9	5.4	165.6	(75.6-314.5)	Female	2	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	23	19.5	118.0	(74.8-177.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.1	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	5	3.7	134.9	(43.5-314.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	68	65.1	104.4	(81.1-132.3)
Female	0	0.3	nc	(nc-nc)	Female	61	54.4	112.1	(85.7-144.0)
<u>Lung and Bronchus</u>									
Male	3	9.1	nc	(nc-nc)					
Female	6	7.2	83.7	(30.6-182.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.3	78.8	(25.4-184.0)	Male	2	4.7	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	22	22.4	98.0	(61.4-148.4)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	9	9.9	90.5	(41.3-171.8)	<u>Ovary</u>				
Female	7	7.7	90.7	(36.3-186.8)	Female	1	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	28	26.3	106.6	(70.8-154.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.9	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	1	4.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	96	93.8	102.3	(82.9-125.0)
Female	0	0.4	nc	(nc-nc)	Female	63	74.4	84.7	(65.1-108.4)
<u>Lung and Bronchus</u>									
Male	15	12.4	120.7	(67.5-199.1)					
Female	14	10.1	138.9	(75.8-233.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	33.8	97.6	(67.2-137.1)	Male	12	21.0	57.3	(29.6-100.1)
Female	12	12.8	93.8	(48.4-163.9)	Female	11	17.6	62.4	(31.1-111.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.8	147.6	(70.7-271.5)	Male	5	5.4	93.4	(30.1-217.9)
Female	5	5.5	90.2	(29.1-210.4)	Female	3	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	17	18.4	92.4	(53.8-148.0)
Female	115	127.4	90.3	(74.5-108.4)	Female	20	16.7	119.6	(73.1-184.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	6	5.9	102.4	(37.4-222.8)	Male	5	13.1	38.2	(12.3-89.1)
<u>Colon / Rectum</u>					Female	5	6.2	81.3	(26.2-189.7)
Male	41	50.3	81.5	(58.4-110.5)	<u>Ovary</u>				
Female	51	49.0	104.0	(77.4-136.8)	Female	12	13.6	88.1	(45.5-153.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	8.7	nc	(nc-nc)	Male	9	10.0	89.7	(40.9-170.3)
Female	1	2.5	nc	(nc-nc)	Female	12	10.6	112.8	(58.2-197.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.9	nc	(nc-nc)	Male	104	129.6	80.3	(65.6-97.3)
Female	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	8.4	59.8	(19.3-139.5)
Male	9	15.6	57.5	(26.3-109.2)	Female	2	5.2	nc	(nc-nc)
Female	5	9.8	51.1	(16.5-119.2)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.2	95.6	(30.8-223.1)
Male	4	5.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	6	5.0	119.0	(43.4-258.9)
<u>Leukemia</u>					Female	16	15.9	100.7	(57.5-163.5)
Male	3	11.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	9.1	77.2	(30.9-159.0)	Female	24	26.9	89.2	(57.2-132.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	7.5	120.3	(54.9-228.5)	Male	368	456.5	80.6	(72.6-89.3)
Female	2	2.6	nc	(nc-nc)	Female	398	439.8	90.5	(81.8-99.8)
<u>Lung and Bronchus</u>									
Male	52	63.6	81.8	(61.1-107.3)					
Female	58	60.6	95.7	(72.6-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	5	6.1	82.0	(26.4-191.3)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	5.5	91.7	(29.5-213.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	4	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	16	19.3	83.1	(47.5-135.0)
Female	0	0.1	nc	(nc-nc)	Female	12	17.9	67.0	(34.6-117.1)
<u>Lung and Bronchus</u>									
Male	1	2.5	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	27.6	119.4	(82.2-167.6)	Male	10	15.2	65.9	(31.5-121.2)
Female	7	11.0	63.7	(25.5-131.3)	Female	13	12.4	105.2	(55.9-179.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.5	110.1	(35.5-257.0)	Male	1	4.2	nc	(nc-nc)
Female	5	3.9	128.1	(41.3-299.0)	Female	2	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	13	13.6	95.4	(50.8-163.2)
Female	93	96.8	96.1	(77.5-117.7)	Female	18	13.7	131.6	(77.9-208.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	3.7	nc	(nc-nc)	Male	12	9.5	126.1	(65.1-220.4)
<u>Colon / Rectum</u>					Female	3	4.9	nc	(nc-nc)
Male	43	39.9	107.8	(78.0-145.2)	<u>Ovary</u>				
Female	42	41.9	100.2	(72.2-135.4)	Female	11	10.6	103.8	(51.7-185.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.9	116.5	(50.2-229.6)	Male	9	8.0	112.2	(51.2-213.0)
Female	3	2.2	nc	(nc-nc)	Female	10	9.2	108.5	(52.0-199.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	103	103.9	99.2	(80.9-120.3)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	10	6.7	149.8	(71.7-275.5)
Male	13	11.7	111.2	(59.1-190.1)	Female	3	4.5	nc	(nc-nc)
Female	6	7.9	76.0	(27.7-165.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	5	4.2	117.8	(38.0-274.8)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	6	9.6	62.5	(22.8-136.0)
Male	11	8.3	132.0	(65.8-236.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.0	114.0	(49.1-224.7)	Female	26	21.1	123.2	(80.5-180.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.6	107.2	(39.1-233.4)	Male	363	355.9	102.0	(91.8-113.0)
Female	1	2.2	nc	(nc-nc)	Female	331	348.2	95.1	(85.1-105.9)
<u>Lung and Bronchus</u>									
Male	52	51.9	100.2	(74.8-131.4)					
Female	43	51.7	83.2	(60.2-112.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	55	58.2	94.4	(71.1-122.9)	Male	34	38.8	87.7	(60.7-122.6)
Female	26	25.0	104.2	(68.0-152.6)	Female	25	37.4	66.8	(43.2-98.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	12.8	109.4	(59.8-183.6)	Male	5	9.3	53.9	(17.4-125.8)
Female	11	11.2	97.8	(48.8-175.0)	Female	7	7.5	92.9	(37.2-191.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	34	33.8	100.7	(69.7-140.7)
Female	215	241.9	88.9	(77.4-101.6)	Female	31	33.4	92.8	(63.0-131.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	12	12.4	97.2	(50.1-169.7)	Male	17	22.5	75.7	(44.1-121.2)
<u>Colon / Rectum</u>					Female	19	12.2	155.2	(93.4-242.4)
Male	76	87.1	87.3	(68.8-109.2)	<u>Ovary</u>				
Female	80	95.7	83.6	(66.3-104.1)	Female	15	26.5	56.6	(31.7-93.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	14.9	107.3	(61.3-174.3)	Male	20	17.1	116.7	(71.2-180.2)
Female	5	4.9	102.8	(33.1-239.8)	Female	15	20.8	72.2	(40.4-119.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	7.9	nc	(nc-nc)	Male	171	219.9	77.7	(66.5-90.3)
Female	8	6.5	122.8	(52.9-242.0)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	23	14.6	157.3	(99.7-236.1)
Male	30	27.2	110.5	(74.5-157.7)	Female	15	10.3	146.2	(81.8-241.2)
Female	9	18.9	47.7	(21.8-90.6)	<u>Testis</u>				
<u>Larynx</u>					Male	19	16.0	118.6	(71.4-185.2)
Male	12	9.2	129.8	(67.0-226.7)	<u>Thyroid</u>				
Female	3	2.9	nc	(nc-nc)	Male	10	10.5	95.5	(45.7-175.7)
<u>Leukemia</u>					Female	35	35.5	98.6	(68.7-137.2)
Male	21	20.8	100.8	(62.4-154.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	23	18.0	127.8	(81.0-191.8)	Female	44	51.0	86.3	(62.7-115.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	23	12.8	179.2	(113.5-268.8)	Male	754	804.9	93.7	(87.1-100.6)
Female	6	5.1	116.8	(42.6-254.2)	Female	786	862.1	91.2	(84.9-97.8)
<u>Lung and Bronchus</u>									
Male	125	109.4	114.2	(95.1-136.1)					
Female	112	117.7	95.2	(78.4-114.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	21.8	96.4	(59.6-147.3)	Male	10	12.0	83.7	(40.1-153.9)
Female	8	8.7	92.1	(39.6-181.4)	Female	17	10.5	162.6	(94.6-260.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.6	139.4	(44.9-325.4)	Male	1	3.3	nc	(nc-nc)
Female	6	3.3	180.5	(65.9-392.9)	Female	4	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	10.8	102.3	(51.0-183.1)
Female	90	77.4	116.3	(93.5-142.9)	Female	12	11.0	108.8	(56.1-190.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	7	7.4	94.3	(37.8-194.3)
<u>Colon / Rectum</u>					Female	7	4.0	177.1	(70.9-364.8)
Male	31	31.4	98.8	(67.1-140.2)	<u>Ovary</u>				
Female	27	33.2	81.3	(53.5-118.2)	Female	12	8.6	139.6	(72.0-243.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	5.4	167.9	(76.6-318.7)	Male	4	6.3	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	11	7.3	151.1	(75.3-270.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	87	79.9	108.9	(87.2-134.3)
Female	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	5.3	nc	(nc-nc)
Male	9	9.1	98.9	(45.1-187.7)	Female	2	3.5	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	5	8.7	57.3	(18.5-133.7)
Male	1	6.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.8	121.0	(48.5-249.4)	Female	17	16.7	101.7	(59.2-162.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.4	nc	(nc-nc)	Male	276	278.0	99.3	(87.9-111.7)
Female	1	1.7	nc	(nc-nc)	Female	285	280.3	101.7	(90.2-114.2)
<u>Lung and Bronchus</u>									
Male	43	40.4	106.4	(77.0-143.3)					
Female	35	40.7	85.9	(59.8-119.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.4	92.4	(29.8-215.6)	Male	4	3.6	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	21	22.1	94.8	(58.7-145.0)	Female	1	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	6	8.4	71.7	(26.2-156.0)	<u>Ovary</u>				
Female	4	7.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	26	22.6	115.2	(75.2-168.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.8	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	68	77.3	87.9	(68.3-111.5)
Female	1	0.4	nc	(nc-nc)	Female	65	71.8	90.5	(69.8-115.3)
<u>Lung and Bronchus</u>									
Male	6	10.4	57.8	(21.1-125.8)					
Female	7	9.4	74.3	(29.8-153.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.5	120.0	(54.8-227.9)	Male	6	5.3	113.9	(41.6-247.9)
Female	2	2.4	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.5	110.8	(35.7-258.5)
Female	47	30.4	154.8	(113.7-205.8)	Female	0	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.3	nc	(nc-nc)
Male	14	11.7	119.7	(65.4-200.9)	<u>Ovary</u>				
Female	12	9.2	130.8	(67.5-228.6)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	36	31.8	113.1	(79.2-156.6)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	1.9	264.9	(85.4-618.2)
Male	6	4.0	150.6	(55.0-327.8)	Female	2	0.9	nc	(nc-nc)
Female	5	2.1	238.1	(76.7-555.6)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.4	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	7	4.3	162.2	(65.0-334.3)
Male	2	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.9	nc	(nc-nc)	Female	7	6.3	110.4	(44.2-227.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.9	nc	(nc-nc)	Male	110	109.9	100.1	(82.3-120.7)
Female	1	0.5	nc	(nc-nc)	Female	117	96.0	121.9	(100.8-146.1)
<u>Lung and Bronchus</u>									
Male	8	14.6	54.7	(23.6-107.8)					
Female	10	12.0	83.2	(39.9-153.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	18.4	119.5	(74.9-180.9)	Male	13	10.8	119.8	(63.7-204.9)
Female	6	7.6	79.3	(29.0-172.6)	Female	5	9.5	52.5	(16.9-122.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	7	9.7	72.2	(28.9-148.8)
Female	50	69.0	72.5	(53.8-95.5)	Female	13	9.7	133.5	(71.0-228.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	8	6.6	120.5	(51.9-237.4)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	34	27.0	126.1	(87.3-176.3)	<u>Ovary</u>				
Female	27	29.4	91.7	(60.4-133.5)	Female	8	7.6	105.8	(45.6-208.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.6	nc	(nc-nc)	Male	5	5.4	93.0	(30.0-217.1)
Female	0	1.5	nc	(nc-nc)	Female	4	6.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	48	67.2	71.4	(52.7-94.7)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	4.5	nc	(nc-nc)
Male	6	8.0	74.8	(27.3-162.8)	Female	0	3.2	nc	(nc-nc)
Female	5	5.5	90.4	(29.1-211.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.7	nc	(nc-nc)
Male	5	2.8	176.7	(57.0-412.5)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	8.1	nc	(nc-nc)
Male	7	6.1	115.1	(46.1-237.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.3	95.2	(30.7-222.2)	Female	22	14.5	151.3	(94.8-229.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.8	nc	(nc-nc)	Male	221	240.7	91.8	(80.1-104.7)
Female	2	1.5	nc	(nc-nc)	Female	207	248.0	83.5	(72.5-95.6)
<u>Lung and Bronchus</u>									
Male	32	33.9	94.3	(64.5-133.1)					
Female	27	35.1	76.9	(50.7-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.3	86.2	(37.1-169.8)	Male	4	5.9	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	5.2	173.7	(79.2-329.7)
Female	46	34.2	134.5	(98.5-179.4)	Female	5	4.3	115.7	(37.3-270.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.6	nc	(nc-nc)
Male	14	13.9	100.5	(54.9-168.7)	<u>Ovary</u>				
Female	22	12.3	178.4	(111.8-270.1)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.9	nc	(nc-nc)	Male	32	35.5	90.1	(61.6-127.2)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	6	2.3	260.1	(95.0-566.2)
Male	2	4.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.3	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.3	nc	(nc-nc)	Female	7	7.2	96.9	(38.8-199.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	121	126.4	95.7	(79.4-114.4)
Female	0	0.7	nc	(nc-nc)	Female	120	115.2	104.2	(86.4-124.6)
<u>Lung and Bronchus</u>									
Male	16	17.4	91.9	(52.5-149.2)					
Female	16	15.7	101.7	(58.1-165.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	12.5	55.9	(22.4-115.2)	Male	9	7.8	115.9	(52.9-220.0)
Female	7	4.2	165.5	(66.3-341.1)	Female	6	6.1	98.3	(35.9-213.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.5	200.1	(64.5-466.9)	Male	2	2.0	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	9	6.8	132.0	(60.2-250.5)
Female	41	44.8	91.6	(65.7-124.3)	Female	9	5.7	159.1	(72.6-302.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	5	5.0	99.8	(32.2-232.9)
<u>Colon / Rectum</u>					Female	5	2.1	234.8	(75.7-548.0)
Male	25	18.8	133.0	(86.1-196.4)	<u>Ovary</u>				
Female	19	16.0	118.5	(71.3-185.0)	Female	4	4.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.3	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	34	49.6	68.6	(47.5-95.9)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	3.1	nc	(nc-nc)
Male	2	5.9	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	8	3.4	237.4	(102.2-467.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.9	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.6	89.5	(28.8-208.9)
Male	2	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.0	166.6	(53.7-388.7)	Female	14	9.6	145.9	(79.7-244.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.8	nc	(nc-nc)	Male	150	171.5	87.5	(74.0-102.6)
Female	0	0.9	nc	(nc-nc)	Female	167	150.7	110.8	(94.6-129.0)
<u>Lung and Bronchus</u>									
Male	25	23.8	105.0	(67.9-155.0)					
Female	27	20.7	130.2	(85.8-189.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	115	136.8	84.1	(69.4-100.9)	Male	42	82.2	51.1	(36.8-69.1)
Female	44	55.9	78.7	(57.2-105.7)	Female	28	76.2	36.7	(24.4-53.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	21	27.8	75.6	(46.8-115.5)	Male	17	21.2	80.0	(46.6-128.2)
Female	20	24.9	80.5	(49.1-124.3)	Female	15	17.1	87.9	(49.2-145.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	3.8	nc	(nc-nc)	Male	61	73.5	83.0	(63.5-106.7)
Female	545	540.8	100.8	(92.5-109.6)	Female	66	73.3	90.0	(69.6-114.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	37	24.5	150.9	(106.3-208.1)	Male	55	49.9	110.3	(83.1-143.6)
<u>Colon / Rectum</u>					Female	22	26.8	82.0	(51.4-124.2)
Male	180	200.6	89.7	(77.1-103.8)	<u>Ovary</u>				
Female	186	213.6	87.1	(75.0-100.5)	Female	39	58.9	66.2	(47.1-90.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	33	34.3	96.2	(66.2-135.1)	Male	40	40.0	100.0	(71.5-136.2)
Female	8	10.9	73.1	(31.5-144.1)	Female	44	46.6	94.4	(68.6-126.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	13	13.5	96.5	(51.3-165.1)	Male	457	504.5	90.6	(82.5-99.3)
Female	11	11.5	95.8	(47.7-171.4)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	53	33.7	157.2	(117.8-205.6)
Male	50	60.5	82.7	(61.4-109.0)	Female	32	22.6	141.3	(96.6-199.5)
Female	48	42.5	113.0	(83.3-149.8)	<u>Testis</u>				
<u>Larynx</u>					Male	24	22.9	104.9	(67.2-156.1)
Male	26	21.2	122.9	(80.3-180.1)	<u>Thyroid</u>				
Female	7	6.5	107.7	(43.2-222.0)	Male	6	19.5	30.8	(11.2-67.0)
<u>Leukemia</u>					Female	50	68.4	73.1	(54.3-96.4)
Male	31	47.1	65.9	(44.7-93.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	32	40.4	79.1	(54.1-111.7)	Female	126	114.7	109.9	(91.5-130.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	28	28.9	96.9	(64.4-140.0)	Male	1608	1812.2	88.7	(84.4-93.2)
Female	6	11.4	52.7	(19.2-114.7)	Female	1776	1903.0	93.3	(89.0-97.8)
<u>Lung and Bronchus</u>									
Male	231	254.3	90.9	(79.5-103.4)					
Female	263	265.6	99.0	(87.4-111.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.0	156.1	(77.8-279.3)	Male	2	4.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	9	4.1	220.4	(100.6-418.4)
Female	25	26.8	93.4	(60.4-137.9)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	7	10.9	64.2	(25.7-132.4)	<u>Ovary</u>				
Female	3	8.2	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	29	29.0	100.0	(66.9-143.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	5	3.6	138.9	(44.8-324.1)	Female	1	0.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.7	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.6	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	87	100.5	86.5	(69.3-106.7)
Female	0	0.5	nc	(nc-nc)	Female	73	84.5	86.4	(67.7-108.6)
<u>Lung and Bronchus</u>									
Male	8	13.6	58.9	(25.4-116.1)					
Female	8	10.6	75.2	(32.4-148.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.2	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	7	12.9	54.1	(21.7-111.5)	Female	2	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	5	6.0	83.6	(27.0-195.2)	<u>Ovary</u>				
Female	1	5.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	12	15.2	79.2	(40.9-138.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.0	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	1.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	40	52.4	76.4	(54.6-104.0)
Female	0	0.3	nc	(nc-nc)	Female	31	45.3	68.5	(46.5-97.2)
<u>Lung and Bronchus</u>									
Male	4	7.7	nc	(nc-nc)					
Female	2	6.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	29.6	121.6	(85.2-168.4)	Male	8	16.6	48.1	(20.7-94.8)
Female	12	11.8	101.9	(52.6-178.0)	Female	10	13.8	72.2	(34.6-132.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.0	139.0	(55.7-286.3)	Male	6	4.5	132.3	(48.3-288.0)
Female	4	4.4	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	15	14.9	100.9	(56.4-166.5)
Female	114	105.1	108.5	(89.5-130.3)	Female	13	14.8	88.1	(46.8-150.6)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	9	4.3	211.5	(96.5-401.5)	Male	9	10.2	87.8	(40.1-166.7)
<u>Colon / Rectum</u>					Female	6	5.3	113.6	(41.5-247.2)
Male	48	42.8	112.1	(82.7-148.7)	<u>Ovary</u>				
Female	58	45.2	128.4	(97.5-165.9)	Female	17	11.4	148.5	(86.5-237.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	7.3	150.5	(75.0-269.3)	Male	6	8.6	69.9	(25.5-152.2)
Female	4	2.3	nc	(nc-nc)	Female	10	9.9	101.1	(48.4-185.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.0	nc	(nc-nc)	Male	136	108.8	125.0	(104.9-147.9)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	7.2	69.4	(22.4-162.0)
Male	19	12.5	151.5	(91.2-236.5)	Female	7	4.8	144.5	(57.9-297.8)
Female	11	8.5	129.6	(64.6-231.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.2	nc	(nc-nc)
Male	6	4.5	133.2	(48.6-290.0)	<u>Thyroid</u>				
Female	3	1.3	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	13	11.2	116.3	(61.9-198.9)
Male	12	9.1	131.4	(67.8-229.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.8	64.4	(20.8-150.3)	Female	12	22.4	53.6	(27.6-93.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	6.0	149.5	(68.2-283.8)	Male	422	380.4	110.9	(100.6-122.0)
Female	1	2.4	nc	(nc-nc)	Female	419	377.2	111.1	(100.7-122.2)
<u>Lung and Bronchus</u>									
Male	58	54.9	105.7	(80.3-136.7)					
Female	71	54.9	129.2	(100.9-163.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	31.0	109.6	(75.9-153.2)	Male	28	18.5	151.2	(100.5-218.6)
Female	11	12.2	90.0	(44.9-161.0)	Female	19	15.8	120.2	(72.3-187.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.9	nc	(nc-nc)	Male	12	4.9	246.2	(127.1-430.2)
Female	2	4.9	nc	(nc-nc)	Female	9	3.7	240.5	(109.8-456.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	16	16.4	97.7	(55.8-158.7)
Female	111	119.2	93.1	(76.6-112.1)	Female	11	15.7	70.0	(34.9-125.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	6	5.0	119.2	(43.5-259.4)	Male	20	11.8	168.9	(103.1-260.9)
<u>Colon / Rectum</u>					Female	8	5.8	137.6	(59.3-271.2)
Male	49	45.9	106.7	(78.9-141.1)	<u>Ovary</u>				
Female	52	46.4	112.1	(83.7-147.0)	Female	16	12.8	124.7	(71.2-202.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	8.0	249.1	(152.1-384.8)	Male	11	9.2	119.7	(59.7-214.2)
Female	5	2.4	209.2	(67.4-488.3)	Female	14	10.1	138.0	(75.4-231.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.4	nc	(nc-nc)	Male	128	120.6	106.1	(88.5-126.2)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	7	7.6	92.2	(36.9-189.9)
Male	10	14.1	70.9	(33.9-130.4)	Female	2	4.9	nc	(nc-nc)
Female	12	9.3	129.7	(66.9-226.6)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.0	174.0	(69.7-358.6)
Male	6	5.0	119.7	(43.7-260.5)	<u>Thyroid</u>				
Female	0	1.5	nc	(nc-nc)	Male	7	4.3	163.8	(65.6-337.4)
<u>Leukemia</u>					Female	13	13.6	95.7	(50.9-163.7)
Male	6	10.0	59.9	(21.9-130.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.2	109.6	(50.0-208.1)	Female	28	25.8	108.6	(72.1-156.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.8	73.7	(23.8-172.1)	Male	465	416.1	111.7	(101.8-122.4)
Female	3	2.5	nc	(nc-nc)	Female	463	412.3	112.3	(102.3-123.0)
<u>Lung and Bronchus</u>									
Male	61	58.8	103.8	(79.4-133.3)					
Female	77	58.6	131.4	(103.7-164.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.2	116.5	(42.5-253.5)	Male	6	3.7	163.5	(59.7-355.8)
Female	3	1.8	nc	(nc-nc)	Female	7	3.0	230.1	(92.2-474.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.1	191.6	(70.0-417.0)
Female	23	22.6	101.8	(64.5-152.8)	Female	0	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	4	8.2	nc	(nc-nc)	<u>Ovary</u>				
Female	9	6.8	131.8	(60.1-250.2)	Female	0	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	30	23.6	127.2	(85.8-181.5)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	3.0	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	76	78.2	97.2	(76.6-121.6)
Female	0	0.4	nc	(nc-nc)	Female	71	70.9	100.1	(78.2-126.3)
<u>Lung and Bronchus</u>									
Male	7	10.3	67.9	(27.2-139.9)					
Female	7	9.0	77.9	(31.2-160.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.8	92.1	(42.0-174.9)	Male	2	5.9	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.2	134.1	(53.7-276.4)
Female	32	34.3	93.3	(63.8-131.7)	Female	5	4.3	115.2	(37.1-268.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.6	nc	(nc-nc)
Male	10	14.6	68.6	(32.8-126.2)	<u>Ovary</u>				
Female	10	12.5	80.1	(38.4-147.4)	Female	4	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.6	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	22	38.5	57.2	(35.8-86.6)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.1	146.0	(53.3-317.8)
Male	4	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.3	nc	(nc-nc)	Female	5	7.3	68.2	(22.0-159.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.2	nc	(nc-nc)	Male	102	132.4	77.0	(62.8-93.5)
Female	1	0.7	nc	(nc-nc)	Female	107	115.6	92.5	(75.8-111.8)
<u>Lung and Bronchus</u>									
Male	21	18.6	113.2	(70.0-173.0)					
Female	18	16.1	112.0	(66.3-176.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	15.8	120.2	(72.3-187.7)	Male	16	10.5	152.0	(86.8-246.9)
Female	6	5.3	112.7	(41.2-245.3)	Female	11	8.4	130.8	(65.2-234.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	3.6	224.7	(96.8-442.8)	Male	3	2.6	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	20	9.1	219.4	(134.0-338.9)
Female	77	63.3	121.6	(96.0-152.0)	Female	9	7.2	124.4	(56.7-236.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.9	nc	(nc-nc)	Male	3	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.9	nc	(nc-nc)
Male	25	24.4	102.4	(66.2-151.1)	<u>Ovary</u>				
Female	25	20.3	123.0	(79.6-181.5)	Female	3	6.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.4	nc	(nc-nc)	Male	5	4.8	103.1	(33.2-240.7)
Female	2	1.0	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	70	67.4	103.9	(81.0-131.3)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	6	3.9	153.1	(55.9-333.3)
Male	4	8.1	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.0	87.0	(34.9-179.3)
Male	6	5.6	108.1	(39.5-235.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.0	149.1	(54.5-324.6)	Female	9	13.4	66.9	(30.5-127.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.0	nc	(nc-nc)	Male	232	227.7	101.9	(89.2-115.9)
Female	0	1.1	nc	(nc-nc)	Female	207	202.3	102.3	(88.9-117.2)
<u>Lung and Bronchus</u>									
Male	23	30.9	74.3	(47.1-111.6)					
Female	19	26.1	72.8	(43.8-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	10	10.1	99.0	(47.4-182.0)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.5	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.8	131.9	(42.5-307.8)	Female	2	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	9.2	109.0	(52.2-200.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	25	34.0	73.4	(47.5-108.4)
Female	0	0.2	nc	(nc-nc)	Female	30	35.3	85.0	(57.3-121.4)
<u>Lung and Bronchus</u>									
Male	2	4.5	nc	(nc-nc)					
Female	3	4.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.4	67.6	(21.8-157.8)	Male	5	5.1	97.2	(31.3-226.9)
Female	2	2.2	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	4.4	135.8	(49.6-295.6)
Female	26	28.5	91.1	(59.5-133.5)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	11	11.6	94.9	(47.3-169.8)	<u>Ovary</u>				
Female	6	8.6	70.1	(25.6-152.5)	Female	4	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	25	31.3	80.0	(51.7-118.1)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	6	3.9	154.4	(56.4-336.1)	Female	1	0.9	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.3	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.1	nc	(nc-nc)
Male	5	2.7	186.7	(60.2-435.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	2	6.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.9	nc	(nc-nc)	Male	96	107.9	89.0	(72.1-108.7)
Female	0	0.5	nc	(nc-nc)	Female	84	90.2	93.2	(74.3-115.3)
<u>Lung and Bronchus</u>									
Male	10	14.3	70.0	(33.5-128.8)					
Female	17	11.3	150.0	(87.3-240.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	19.4	61.9	(32.0-108.2)	Male	24	10.9	220.9	(141.5-328.7)
Female	7	7.7	91.4	(36.6-188.4)	Female	20	9.1	219.1	(133.8-338.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.3	nc	(nc-nc)	Male	6	3.0	201.8	(73.7-439.3)
Female	2	2.9	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	9.7	123.3	(63.6-215.4)
Female	72	69.6	103.4	(80.9-130.2)	Female	14	9.7	144.8	(79.1-243.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	2.8	nc	(nc-nc)	Male	3	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	20	28.0	71.4	(43.6-110.2)	<u>Ovary</u>				
Female	34	30.2	112.7	(78.0-157.5)	Female	14	7.6	185.1	(101.1-310.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.7	nc	(nc-nc)	Male	9	5.6	159.8	(72.9-303.4)
Female	0	1.5	nc	(nc-nc)	Female	8	6.5	122.4	(52.7-241.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	69	68.8	100.3	(78.0-126.9)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	4.7	nc	(nc-nc)
Male	10	8.1	123.6	(59.2-227.3)	Female	2	3.3	nc	(nc-nc)
Female	4	5.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	9	7.4	122.1	(55.7-231.7)
Male	14	6.0	233.3	(127.4-391.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	5.2	173.1	(79.0-328.6)	Female	15	14.6	102.9	(57.6-169.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.9	nc	(nc-nc)	Male	248	245.4	101.1	(88.9-114.5)
Female	1	1.6	nc	(nc-nc)	Female	269	248.0	108.5	(95.9-122.3)
<u>Lung and Bronchus</u>									
Male	27	35.0	77.2	(50.9-112.3)					
Female	26	34.9	74.6	(48.7-109.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	20.0	109.8	(68.8-166.2)	Male	10	11.9	84.3	(40.4-155.1)
Female	12	7.4	162.9	(84.1-284.5)	Female	7	9.5	73.8	(29.6-152.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	5	2.9	170.7	(55.0-398.4)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	10.5	66.6	(26.7-137.2)
Female	56	72.0	77.7	(58.7-101.0)	Female	11	9.5	116.1	(57.9-207.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	3.0	166.3	(53.6-388.2)	Male	7	7.6	91.7	(36.8-189.0)
<u>Colon / Rectum</u>					Female	1	3.5	nc	(nc-nc)
Male	33	29.6	111.3	(76.6-156.3)	<u>Ovary</u>				
Female	38	28.0	135.7	(96.0-186.2)	Female	4	7.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.2	nc	(nc-nc)	Male	7	5.9	118.0	(47.3-243.2)
Female	0	1.4	nc	(nc-nc)	Female	6	6.1	97.8	(35.7-212.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.5	nc	(nc-nc)	Male	74	77.3	95.8	(75.2-120.2)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	4.9	nc	(nc-nc)
Male	5	9.0	55.4	(17.9-129.3)	Female	2	2.9	nc	(nc-nc)
Female	7	5.6	125.2	(50.2-258.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	8	8.1	98.9	(42.6-195.0)
Male	4	6.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.9	101.9	(32.8-237.8)	Female	17	15.5	109.4	(63.7-175.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.4	137.3	(50.1-298.8)	Male	277	267.1	103.7	(91.8-116.6)
Female	3	1.5	nc	(nc-nc)	Female	238	248.6	95.7	(84.0-108.7)
<u>Lung and Bronchus</u>									
Male	56	37.7	148.4	(112.1-192.7)					
Female	26	35.4	73.3	(47.9-107.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	70	54.2	129.1	(100.6-163.1)	Male	16	33.7	47.5	(27.1-77.1)
Female	19	21.7	87.7	(52.8-137.0)	Female	24	29.7	80.8	(51.7-120.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.0	90.8	(43.5-167.0)	Male	9	8.6	104.8	(47.8-199.0)
Female	9	9.4	95.8	(43.7-181.8)	Female	7	6.6	106.0	(42.4-218.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	27	29.7	91.0	(60.0-132.4)
Female	199	211.8	94.0	(81.4-108.0)	Female	29	28.5	101.9	(68.2-146.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	11	9.7	113.5	(56.6-203.0)	Male	25	20.9	119.7	(77.4-176.7)
<u>Colon / Rectum</u>					Female	10	10.4	96.3	(46.1-177.2)
Male	81	80.7	100.4	(79.7-124.8)	<u>Ovary</u>				
Female	81	83.3	97.2	(77.2-120.9)	Female	20	22.9	87.4	(53.4-135.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	14.0	85.7	(44.2-149.7)	Male	18	16.1	112.1	(66.4-177.1)
Female	6	4.2	141.7	(51.8-308.5)	Female	19	18.1	105.0	(63.2-164.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.1	117.4	(42.9-255.5)	Male	217	209.1	103.8	(90.4-118.5)
Female	3	4.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	27	13.4	201.4	(132.7-293.0)
Male	36	25.1	143.7	(100.6-198.9)	Female	13	8.9	146.6	(78.0-250.7)
Female	17	16.4	103.4	(60.2-165.6)	<u>Testis</u>				
<u>Larynx</u>					Male	9	9.2	98.1	(44.8-186.3)
Male	18	8.8	205.7	(121.9-325.1)	<u>Thyroid</u>				
Female	2	2.5	nc	(nc-nc)	Male	8	8.2	97.3	(41.9-191.7)
<u>Leukemia</u>					Female	31	26.7	116.2	(79.0-165.0)
Male	11	18.3	60.0	(29.9-107.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	15.4	103.6	(59.2-168.3)	Female	42	44.9	93.6	(67.4-126.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	11.9	109.1	(58.0-186.6)	Male	819	735.9	111.3	(103.8-119.2)
Female	4	4.4	nc	(nc-nc)	Female	723	740.1	97.7	(90.7-105.1)
<u>Lung and Bronchus</u>									
Male	137	102.5	133.7	(112.2-158.0)					
Female	115	102.5	112.2	(92.6-134.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.6	nc	(nc-nc)	Male	7	4.8	145.3	(58.2-299.4)
Female	1	2.7	nc	(nc-nc)	Female	0	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	20	27.0	73.9	(45.2-114.2)	Female	4	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.3	nc	(nc-nc)
Male	9	11.5	78.0	(35.6-148.1)	<u>Ovary</u>				
Female	8	10.3	77.8	(33.5-153.4)	Female	6	2.9	207.5	(75.8-451.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	32	30.7	104.4	(71.4-147.4)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	1.9	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.3	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.9	nc	(nc-nc)	Female	12	5.7	210.0	(108.4-366.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	97	105.7	91.8	(74.4-112.0)
Female	0	0.5	nc	(nc-nc)	Female	88	92.7	94.9	(76.1-116.9)
<u>Lung and Bronchus</u>									
Male	20	14.6	136.8	(83.5-211.2)					
Female	13	12.8	101.7	(54.1-173.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	28.5	70.1	(42.8-108.2)	Male	19	18.4	103.1	(62.1-161.0)
Female	19	10.3	183.7	(110.6-286.9)	Female	18	15.2	118.1	(70.0-186.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.0	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	5	4.8	104.6	(33.7-244.1)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	16	16.0	99.8	(57.0-162.1)
Female	114	112.5	101.4	(83.6-121.8)	Female	15	13.8	108.8	(60.9-179.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	8	5.2	154.9	(66.7-305.3)	Male	15	12.0	125.4	(70.1-206.8)
<u>Colon / Rectum</u>					Female	6	5.3	114.1	(41.7-248.4)
Male	47	43.3	108.5	(79.7-144.3)	<u>Ovary</u>				
Female	47	38.7	121.5	(89.2-161.5)	Female	13	11.9	109.6	(58.3-187.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	7.7	77.8	(28.4-169.3)	Male	14	8.6	162.3	(88.7-272.3)
Female	0	2.0	nc	(nc-nc)	Female	8	8.4	94.9	(40.8-186.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.6	nc	(nc-nc)	Male	119	117.8	101.0	(83.7-120.9)
Female	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	7.1	nc	(nc-nc)
Male	14	14.0	100.0	(54.6-167.8)	Female	4	4.0	nc	(nc-nc)
Female	12	8.4	143.6	(74.1-250.9)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.6	152.3	(61.0-313.8)
Male	2	4.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	5	4.6	108.8	(35.1-253.8)
<u>Leukemia</u>					Female	16	14.2	112.7	(64.4-183.1)
Male	5	9.7	51.4	(16.6-119.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	7.3	123.1	(56.2-233.7)	Female	28	24.4	115.0	(76.4-166.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	6.7	223.5	(125.0-368.6)	Male	416	401.8	103.5	(93.8-114.0)
Female	2	2.1	nc	(nc-nc)	Female	427	373.3	114.4	(103.8-125.8)
<u>Lung and Bronchus</u>									
Male	70	55.2	126.7	(98.8-160.1)					
Female	69	51.1	134.9	(105.0-170.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.8	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	9	2.5	359.0	(163.8-681.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	26	19.3	134.9	(88.1-197.7)	Female	1	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	4	7.0	nc	(nc-nc)	<u>Ovary</u>				
Female	5	8.3	60.2	(19.4-140.6)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	22	17.4	126.5	(79.2-191.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.0	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.0	nc	(nc-nc)	Male	73	61.9	117.9	(92.4-148.3)
Female	1	0.4	nc	(nc-nc)	Female	76	69.0	110.2	(86.8-137.9)
<u>Lung and Bronchus</u>									
Male	15	8.8	169.6	(94.9-279.7)					
Female	12	10.0	119.8	(61.9-209.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	8.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	4.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.2	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	8.0	nc	(nc-nc)	Male	8	4.7	171.8	(74.0-338.5)
Female	4	2.7	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
Female	31	26.9	115.1	(78.2-163.3)	Female	3	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	1.1	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	10	11.9	84.3	(40.4-155.1)	<u>Ovary</u>				
Female	19	10.1	187.9	(113.1-293.4)	Female	4	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.1	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	39	31.1	125.4	(89.2-171.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	2.0	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.0	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.8	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.8	nc	(nc-nc)	Male	100	106.6	93.8	(76.3-114.1)
Female	0	0.5	nc	(nc-nc)	Female	102	91.5	111.5	(90.9-135.4)
<u>Lung and Bronchus</u>									
Male	11	15.2	72.3	(36.0-129.3)					
Female	5	12.9	38.7	(12.5-90.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	6.1	163.8	(78.4-301.2)	Male	6	4.7	128.2	(46.8-279.1)
Female	3	2.3	nc	(nc-nc)	Female	5	4.1	122.4	(39.4-285.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.0	125.6	(40.5-293.0)
Female	29	28.8	100.8	(67.5-144.7)	Female	2	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	13	9.8	132.0	(70.2-225.8)	<u>Ovary</u>				
Female	7	8.7	80.7	(32.3-166.2)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	26	26.3	98.7	(64.4-144.6)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.2	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.8	nc	(nc-nc)	Female	7	5.9	119.2	(47.8-245.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.7	nc	(nc-nc)	Male	100	93.2	107.3	(87.3-130.5)
Female	0	0.5	nc	(nc-nc)	Female	88	90.8	96.9	(77.7-119.4)
<u>Lung and Bronchus</u>									
Male	13	12.0	108.6	(57.8-185.8)					
Female	16	11.3	142.1	(81.2-230.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	6	1.4	420.6	(153.6-915.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	10	11.1	90.2	(43.2-165.9)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	7	4.7	148.3	(59.4-305.5)	<u>Ovary</u>				
Female	4	4.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	21	12.2	172.8	(106.9-264.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	3	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	64	41.9	152.8	(117.7-195.1)
Female	0	0.2	nc	(nc-nc)	Female	36	37.1	97.0	(67.9-134.3)
<u>Lung and Bronchus</u>									
Male	9	6.0	149.3	(68.1-283.4)					
Female	5	5.2	95.3	(30.7-222.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.4	149.0	(74.3-266.6)	Male	3	5.6	nc	(nc-nc)
Female	7	2.6	265.6	(106.4-547.3)	Female	7	4.9	142.1	(56.9-292.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	4.7	105.3	(33.9-245.8)
Female	41	33.6	122.1	(87.6-165.7)	Female	4	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	6	3.6	167.8	(61.3-365.3)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	20	11.7	170.4	(104.0-263.1)	<u>Ovary</u>				
Female	11	10.1	109.0	(54.3-195.0)	Female	3	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	8	2.1	373.3	(160.8-735.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	29	30.7	94.4	(63.2-135.6)
Female	3	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	1.9	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.1	97.6	(31.5-227.8)
Male	2	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.2	228.6	(73.7-533.4)	Female	7	6.9	101.4	(40.6-209.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.0	nc	(nc-nc)	Male	121	110.6	109.4	(90.8-130.8)
Female	0	0.6	nc	(nc-nc)	Female	129	106.8	120.8	(100.9-143.6)
<u>Lung and Bronchus</u>									
Male	19	14.3	132.5	(79.7-206.9)					
Female	16	13.2	121.5	(69.4-197.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.8	77.0	(28.1-167.5)
Female	0	0.0	nc	(nc-nc)	Female	3	6.0	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	4.8	165.8	(71.4-326.6)	Male	3	3.4	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	25	21.1	118.6	(76.7-175.1)	Female	1	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	4	7.6	nc	(nc-nc)	<u>Ovary</u>				
Female	12	7.3	164.0	(84.6-286.5)	Female	3	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	24	20.0	120.3	(77.1-179.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	5	2.6	195.8	(63.1-456.9)	Female	1	0.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.9	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.5	nc	(nc-nc)	Female	7	4.3	162.5	(65.1-334.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	65	70.3	92.5	(71.4-117.9)
Female	0	0.4	nc	(nc-nc)	Female	86	69.9	123.1	(98.5-152.0)
<u>Lung and Bronchus</u>									
Male	7	9.3	75.4	(30.2-155.3)					
Female	6	9.0	66.5	(24.3-144.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	9.2	205.4	(123.6-320.8)	Male	6	6.4	94.5	(34.5-205.6)
Female	6	3.7	160.7	(58.7-349.7)	Female	4	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.5	109.0	(39.8-237.2)
Female	50	40.0	124.9	(92.7-164.6)	Female	9	5.0	178.6	(81.5-339.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.9	nc	(nc-nc)
Male	19	14.2	133.8	(80.5-208.9)	<u>Ovary</u>				
Female	17	14.3	119.0	(69.3-190.6)	Female	4	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.5	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	41	37.3	109.9	(78.8-149.0)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.3	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	5	3.0	168.3	(54.2-392.8)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.5	145.3	(62.5-286.2)
Male	3	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	11	8.3	133.0	(66.3-238.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.2	nc	(nc-nc)	Male	142	132.3	107.3	(90.4-126.5)
Female	2	0.8	nc	(nc-nc)	Female	165	135.0	122.3	(104.3-142.4)
<u>Lung and Bronchus</u>									
Male	21	17.9	117.6	(72.8-179.8)					
Female	22	17.9	122.7	(76.9-185.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	28.2	74.5	(46.1-113.8)	Male	18	16.8	107.1	(63.4-169.2)
Female	16	11.4	140.3	(80.1-227.8)	Female	18	14.4	124.6	(73.8-196.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.3	94.4	(30.4-220.3)	Male	8	4.4	182.2	(78.4-359.0)
Female	2	4.5	nc	(nc-nc)	Female	5	3.5	143.5	(46.2-334.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	18	14.9	121.1	(71.7-191.4)
Female	106	107.1	99.0	(81.0-119.7)	Female	14	14.6	95.8	(52.3-160.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	6	4.6	130.3	(47.6-283.6)	Male	2	10.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	5.3	nc	(nc-nc)
Male	39	41.5	94.0	(66.8-128.5)	<u>Ovary</u>				
Female	40	44.1	90.6	(64.7-123.4)	Female	16	11.6	138.2	(78.9-224.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.2	nc	(nc-nc)	Male	6	8.3	72.3	(26.4-157.4)
Female	0	2.2	nc	(nc-nc)	Female	5	9.6	52.1	(16.8-121.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	133	106.0	125.5	(105.1-148.7)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	6.9	nc	(nc-nc)
Male	13	12.6	102.8	(54.7-175.9)	Female	6	4.7	126.8	(46.3-276.0)
Female	7	8.4	83.1	(33.3-171.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.8	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	10	3.9	256.6	(122.8-471.9)
<u>Leukemia</u>					Female	12	12.3	97.7	(50.4-170.6)
Male	10	9.1	110.0	(52.7-202.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.8	102.3	(44.0-201.5)	Female	17	22.5	75.6	(44.0-121.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	6.1	164.8	(78.9-303.2)	Male	380	373.2	101.8	(91.9-112.6)
Female	2	2.3	nc	(nc-nc)	Female	364	377.6	96.4	(86.7-106.8)
<u>Lung and Bronchus</u>									
Male	37	52.9	69.9	(49.2-96.4)					
Female	45	53.2	84.5	(61.6-113.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	11	6.4	171.2	(85.3-306.3)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.8	nc	(nc-nc)	Female	4	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	6.5	107.3	(43.0-221.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.9	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	26	21.6	120.6	(78.7-176.7)
Female	0	0.1	nc	(nc-nc)	Female	24	19.8	121.1	(77.6-180.2)
<u>Lung and Bronchus</u>									
Male	4	2.8	nc	(nc-nc)					
Female	2	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;